Zeposia (Ozanimod)

Generic Name

Ozanimod

Brand Names

Zeposia, ZEPOSIA 7-Day

FDA approval date: March 27, 2020

Classification: Sphingosine 1-phosphate Receptor Modulator

Form: Kit, Capsule

What is Zeposia (Ozanimod)?

ZEPOSIA is indicated for the treatment of: relapsing forms of multiple sclerosis , to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults., moderately to severely active ulcerative colitis in adults. ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of:, Relapsing forms of multiple sclerosis , to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. , Moderately to severely active ulcerative colitis in adults.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Real-world Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis: A Chart Review Study

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug

Summary: The purpose of this study is to evaluate the effectiveness and safety of ozanimod vs azathioprine for the treatment of ulcerative colitis (UC) in real-world clinical practice in Japan

A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy

Who is this study for: Patients with Ulcerative Colitis

Enrollment Status: Recruiting

Publish Date: April 07, 2026

Intervention Type: Drug

Study Drug: Ozanimod

Study Phase: Phase 2/Phase 3

Summary: The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Enrollment Status: Recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

View All Clinical Trials